teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 43 Projects Releases Packages Wiki Activity Actions 422
teleo-codex/entities/health/apotex.md
Teleo Agents 1b0cc94a3b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
vida: extract claims from 2026-04-21-apotex-fda-tentative-approval-generic-semaglutide 
- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-04-21 04:49:34 +00:00

1.1 KiB
Raw Blame History

type entity_type name domain status founded headquarters website tags
entity company Apotex Inc. health active null Canada https://www.apotex.com
generic-pharmaceuticals
semaglutide
GLP-1
biosimilar

Apotex Inc.

Canadian generic pharmaceutical manufacturer.

Overview

Apotex is a generic pharmaceutical company that received the first US FDA tentative approval for generic semaglutide injection in partnership with Orbicular Pharmaceutical Technologies.

Timeline

  • 2026-04-10 — Received first US FDA tentative approval for generic semaglutide injection (ANDA) in partnership with Orbicular Pharmaceutical Technologies. As first ANDA filer, would receive 180 days of market exclusivity upon commercial launch. Tentative approval confirms application meets FDA standards but does not permit marketing due to Novo Nordisk patent barriers extending to December 5, 2031.

Strategic Position

First-mover position in US generic semaglutide market with regulatory approval complete but commercial launch blocked by patent thicket. Realistic market entry: 2031-2033.